Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Abstract Introduction Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLARITY, a second head-to-head trial comparing secukin...

Full description

Bibliographic Details
Main Authors: Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-10-01
Series:Dermatology and Therapy
Subjects:
Moderate to severe psoriasis
Secukinumab
Ustekinumab
Online Access:http://link.springer.com/article/10.1007/s13555-018-0265-y

Internet

http://link.springer.com/article/10.1007/s13555-018-0265-y

Similar Items